Search clinical trials for: tyrosine kinase inhibitor

Total 68084 results

Gene Solutions

Recruiting

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

Non Small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage IIIC Non-Small Cell Lung Cancer | Tyrosine Kinase Inhibitors

Vietnam
National Cancer Institute (NCI)

Not yet recruiting

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Neoplasms

United States
Mayo Clinic

Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hematopoietic and Lymphoid System Neoplasm

United States
Peking Union Medical College
Peking University Hospital of Stomatology

Recruiting

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Precision Therapy | Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma | Neoadjuvant or Conversion Therapy

China
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Carcinoma, Non-Small-Cell Lung

Japan, China, Canada, Spain, Germany, Korea, Republic of, Austria, Brazil, Greece, Romania, France, United States, Italy, Argentina, Chile, Hungary, India, Poland, Turkey, Switzerland, Netherlands
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel, Taiwan, United Kingdom, Chile, Canada, Japan, Brazil
University Hospital, Caen

Not yet recruiting

IRAF-ABLATION Study: a Multicenter International Retrospective Cohort of Patients With BTK Inhibitors-related AF Treated by Catheter Ablation

Hematologic Malignancy | BTKi-induced Atrial Fibrillation | Atrial Fibrillation Catheter Ablation

France
National Cancer Institute (NCI)

Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm

United States
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
AbbVie

Recruiting

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain (PROVIDENCE)

Chronic Lymphocytic Leukemia

Spain
Assiut University

Not yet recruiting

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

CML, Chronic Phase
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network; Puma Biotechnology, Inc.

Recruiting

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Gastric Cancer | GastroEsophageal Cancer

United States
Novartis Pharmaceuticals

Recruiting

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (ASSURE-3)

Chronic Myeloid Leukemia

France
National Cancer Institute (NCI)

Recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid Malignancies

United States
University of Milano Bicocca

Recruiting

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer (MUT-ONC)

Lung Cancer

Italy
BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

Australia, United States, New Zealand, Korea, Republic of, Canada, Puerto Rico
Beijing 302 Hospital

Recruiting

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

China
Goethe University
German Federal Ministry of Education and Research; Deutsche Leukämie- & Lymphom-Hilfe

Recruiting

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT (GMALL-EVOLVE)

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Ph+ ALL

China
Sun Yat-sen University
First People's Hospital of Foshan; The First Affiliated Hospital, Guangzhou... and other collaborators

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (HAIC)

Hepatocellular Carcinoma | Chemotherapy Effect | Chemotherapeutic Toxicity

China
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Renal Cell Carcinoma
Alvaro Alencar, MD
Incyte Corporation; BeiGene; MorphoSys AG

Not yet recruiting

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma (ZANU-TAFA)

Mantle Cell Lymphoma

United States
Kura Oncology, Inc.
Mirati Therapeutics Inc.

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001)

Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Carcinoma (ccRCC) | Solid Tumors With HRAS Alterations

United States
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
Kura Oncology, Inc.

Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Neoplasms by Histologic Type | Acute Myeloid Leukemia | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | AML | Acute Leukemia | Hematologic Malignancy | NPM1 Mutation | AML With Mutated NPM1 | KMT2Ar | MLL Rearrangement

United States
Joshua Palmer
Genentech, Inc.

Recruiting

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE)

NSCLC | Lung Cancer | Brain Metastases

United States
Medical College of Wisconsin

Not yet recruiting

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma
IDEAYA Biosciences

Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Canada, Israel, Spain, Australia, Germany, France, Italy, United Kingdom, Netherlands, Belgium, Poland, Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
ONY
Avania

Not yet recruiting

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS (Aero-05)

Intubation Complication | Death; Neonatal | Respiratory Distress Syndrome (Neonatal)

United States
University Hospital, Clermont-Ferrand
Centre Hospitalier Universitaire de Saint Etienne; Central Hospital, Nancy,... and other collaborators

Recruiting

Chronic Myeloid Leukemia (CML) Real-Life Database

Chronic Myeloid Leukemia (CML)

France
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States, Spain
Genentech, Inc.

Recruiting

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Colorectal Cancer | Non-Small Cell Lung Cancer

Korea, Republic of, Australia, Canada, United States
AstraZeneca

Recruiting

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

Mantle Cell Lymphoma (MCL)

Canada, Poland, United Kingdom, United States, Brazil, Spain, Australia
Incyte Corporation

Recruiting

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United Kingdom, Italy, France, Belgium, Hungary
The First Affiliated Hospital with Nanjing Medical...
AstraZeneca

Recruiting

A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

Chronic Lymphocytic Leukemia

China
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Novartis Pharmaceuticals

Recruiting

Asciminib RMP Study

Chronic Myeloid Leukemia

Korea, Republic of
Academisch Medisch Centrum - Universiteit van Amsterdam...
Comprehensive Cancer Centre The Netherlands

Not yet recruiting

Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy (PrimerX)

Renal Cell Carcinoma
Fundaleu

Recruiting

Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase (AST)

CML

Argentina
Chen Miao

Recruiting

Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

Warm Autoimmune Hemolytic Anemia

China
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Disorders | Hb-SS Disease | Hemoglobin S | Disease Sickle Cell Anemia | Hemoglobin Beta Thalassemia Disease

United States
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Non-small-cell Lung Carcinoma

China
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
University of Colorado, Denver
Janssen Research & Development, LLC

Recruiting

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Lung Cancer | Non Small Cell Lung Cancer

United States
Sun Yat-sen University

Not yet recruiting

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Cervical Cancer | Cervical Carcinoma

China
Fujian Cancer Hospital

Recruiting

HRQOL in Locally Advanced Thyroid Carcinoma (LATCQOL)

Thyroid Cancer | Health Related Quality of Life | Tyrosine Kinase Inhibitor

China
Sun Yat-sen University

Not yet recruiting

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Endometrial Cancer | Endometrial Adenocarcinoma

China

Search clinical trials for: tyrosine kinase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations